STR Biotech Home
STR Biotech is a privately held, biopharmaceutical company focused on developing
phagocytosis enhancer for the support treatment of cancer,
autoimmune and other serious diseases.
The Company’s scientific advisors have significant expertise covering
the development of biomedicine to regulation of GMP. At STR Biotech we currently
selectively engage an innate immunity for treatment cachexia and neutropenia
induced by anticancer drug.
Toloran4, developed through the company’s own highly active innate immunity
development program, mediated TLR4 of innate immune cells and enhances
phagocytosis (and endocytosis), and as a result, it can resolve inflammation in
our body by rapidly removing surrounding DAMPs.
In addition to the opportunity in cancer induced neutropenia, Toloran4 will be also
evaluated in Th2 biased disease like allergic rhinitis to asthma because
phagocytosis can induce Th1 immune responses.
